Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00501293 · ClinicalTrials.gov registry record · Phase 3
Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
A Phase 3 study, sponsored by Noven Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
NCT00501293 is a Phase 3 study that has completed, run by Noven Therapeutics. The registered enrollment target is 163 participants.
The verdict
NCT00501293, a Phase 3 study, has completed, sponsored by Noven Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
Study Summary
To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
Interventions
- DRUG Methylphenidate Transdermal System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00501293
The ClinicalTrials.gov registry entry for NCT00501293 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Noven Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Methylphenidate Transdermal System is the first listed.
NCT00501293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00501293 about?
NCT00501293 is a clinical study titled "Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD". To evaluate the long-term, safety of Methylphenidate Transdermal System (MTS) in aged 13-17 years diagnosed withADHD
What is the current status of trial NCT00501293?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2007-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00501293?
The interventions under investigation include: Methylphenidate Transdermal System (DRUG).
Who is sponsoring clinical trial NCT00501293?
This trial is sponsored by Noven Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.